Moderna mentioned on Thursday that it’s growing a single-dose vaccine that mixes a booster dose in opposition to Covid-19 and a booster dose in opposition to the flu.
“Our primary precedence as an organization at present is to convey to market an annual respiratory booster vaccine, which we plan to all the time customise and improve,” mentioned CEO Stéphane Bancel mentioned throughout Moderna’s R&D day for buyers.
The corporate supplied an replace on the continued mid-stage trial of its approved Covid vaccine in kids 6 months to beneath 12 years of age.
Moderna’s vaccine, which obtained emergency approval for folks 18 years of age and older in the USA in December, is at present beneath FDA overview to be used in adolescents.
As a part of a kids’s trial, the corporate mentioned it is going to take a look at 50 micrograms of its vaccine in a examine group of 4,000 kids ages 6 to beneath 12.
Moderna says that dose choice research for various age teams, comparable to ages 2 to beneath 6, and 6 months to beneath 2, are nonetheless ongoing.
Pfizer Inc’s rival vaccine and German companion BioNTech have been approved for ages 12 to fifteen earlier this yr.
On Wednesday, Novavax mentioned it had begun an early-stage examine to check a mixed flu and Covid vaccine.